TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16885248

Group type: EXPERIMENTAL
Intervention: Consultations involving product requests
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Consensus group assessment (stage 1)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Expert group assessment (stage 2)
Number of subjects: 364
Study: 15492650

Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 8 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 10 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 12 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 14 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 16 mm Hg
Number of subjects: 100
Study: 11280362

Group type: EXPERIMENTAL
Intervention: Self-tapping implants
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ICE implants
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both self-tapping and ICE implants
Number of subjects: 189
Study: 9174453

Group type: EXPERIMENTAL
Intervention: Cementless knee prostheses (3 designs)
Number of subjects: 42
Study: 2948526

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (400 micrograms)
Number of subjects: 14
Study: 29663011

Group type: EXPERIMENTAL
Intervention: MedDiet+extra‐virgin olive oil
Number of subjects: 945

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: MedDiet+nuts
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Highest quartile of phenylalanine
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Highest quartile of leucine
Number of subjects: 945
Study: 27217043

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 189
Study: 24382690

Group type: EXPERIMENTAL
Intervention: Optimize group (telbivudine for 24 weeks, then telbivudine plus adefovir until week 104 for suboptimal responders)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Mono group (telbivudine monotherapy)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: telbivudine plus adefovir (for week 24 suboptimal responders)
Number of subjects: 606

Group type: COMPARATOR
Intervention: telbivudine monotherapy
Number of subjects: 606
Study: 23208461

Group type: EXPERIMENTAL
Intervention: GH/HMG/GnRHant group (n=40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: HMG/GnRHant group (n=42)
Number of subjects: 82
Study: 20385680

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Local guidelines recommending routine use of oxygen
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Belief in oxygen's effectiveness
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Concerns about oxygen therapy
Number of subjects: 524
Study: 18222241

Group type: EXPERIMENTAL
Intervention: Retrograde hot-shot cardioplegia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cold-blood cardioplegia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 16754218

Group type: EXPERIMENTAL
Intervention: Cryo-preparation (local ice application before injection)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No cryo-preparation (standard local anaesthetic injection)
Number of subjects: 39
Study: 12663710

Group type: EXPERIMENTAL
Intervention: RT+TAB
Number of subjects: 149

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 149
Study: 10837839

Group type: EXPERIMENTAL
Intervention: Regular Diet Coke (76 mg caffeine)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Caffeine-free Diet Coke (10 mg caffeine)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both beverages (Regular and Caffeine-free Diet Coke)
Number of subjects: 11
Study: 8644660

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 356

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 356
Study: 1632305

Group type: EXPERIMENTAL
Intervention: Ciprostene
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3777568

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study: 31494254

Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx® (2 sachets twice daily for 2 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29351383

Group type: EXPERIMENTAL
Intervention: Multi-joint exercises (MJ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined multi- and single-joint exercises (MJ+SJ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 27597270

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 400

Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 400
Study: 25415784

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic only
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic and steroid
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic and steroid
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic only
Number of subjects: 220
Study: 22721899

Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide (ViCPS) vaccine
Number of subjects: 27231

Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 27231
Study: 20178577

Group type: EXPERIMENTAL
Intervention: Mismatch conditions in an auditory identification task
Number of subjects: 14
Study: 18628532

Group type: EXPERIMENTAL
Intervention: High-risk pregnancy screening
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Maternal age and parity
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Maternal educational attainment
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 299
Study: 18325758

Group type: EXPERIMENTAL
Intervention: Testosterone patch 30 cm2 (0.5mg/cm2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testosterone patch 45 cm2 (0.5mg/cm2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testosterone patch 60 cm2 (0.5mg/cm2)
Number of subjects: 24
Study: 15073677

Group type: EXPERIMENTAL
Intervention: Smallpox immunization with vaccinia virus (VV)
Number of subjects: 0
Study: 11739447

Group type: EXPERIMENTAL
Intervention: CCK-8, 1 ng/kg per min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCK-8, 3 ng/kg per min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCK-8 infusion
Number of subjects: 24
Study: 9422926

Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 127
Study: 7684118

Group type: EXPERIMENTAL
Intervention: Isoprinosine (3 g/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3320786

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Propranolol
Number of subjects: 13
Study: 31084359

Group type: EXPERIMENTAL
Intervention: Diffusive chaos method
Number of subjects: 135
Study: 28566070

Group type: EXPERIMENTAL
Intervention: Quality improvement initiative comprising point‐of‐care electronic decision support with audit and feedback tools
Number of subjects: 53164
Study: 25612299

Group type: EXPERIMENTAL
Intervention: Ponesimod 2.5 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 5 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg q.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg q.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg single dose after washout period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 2.5 mg b.i.d. and 5 mg b.i.d. morning doses
Number of subjects: 0
Study: 23930631

Group type: EXPERIMENTAL
Intervention: 3 percent sodium hypochlorite (NaOCl)
Number of subjects: 100

Group type: COMPARATOR
Intervention: formocresol (FC)
Number of subjects: 100
Study: 21114477

Group type: EXPERIMENTAL
Intervention: Moisturizer containing formaldehyde (2000 p.p.m.)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Moisturizer without formaldehyde
Number of subjects: 37
Study: 19858753

Group type: EXPERIMENTAL
Intervention: Creatine + D-pinitol (CRP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Creatine monohydrate (CR)
Number of subjects: 24
Study: 16768642

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18-72 mg/day
Number of subjects: 171
Study: 15315724

Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 40
Study: 11167103

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 9266276

Group type: EXPERIMENTAL
Intervention: ABT-299 0.8 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ABT-299 2 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ABT-299 70 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8281717

Group type: EXPERIMENTAL
Intervention: Hollow fiber dialyzer GF 120M
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plate dialyzer Lundia IC5N
Number of subjects: 14
Study: 3822616

Group type: EXPERIMENTAL
Intervention: ketoconazole (5 mg/kg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: griseofulvin (15 mg/kg/day)
Number of subjects: 80
Study: 29803589

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study: 27491620

Group type: EXPERIMENTAL
Intervention: SL group (lowered glycogen availability)
Number of subjects: 21

Group type: COMPARATOR
Intervention: CON group (maintained glycogen availability)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SL group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study: 24297666

Group type: EXPERIMENTAL
Intervention: Feedback on knowledge
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Feedback on quality of care
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Useful feedback on knowledge
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Useful feedback on clinical care
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Participation in knowledge assessment programs
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Demonstrating knowledge via examination
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Public availability of competence information
Number of subjects: 446
Study: 22503494

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1000 mg of paracetamol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous injection of 50 mg of pethidine hydrochloride
Number of subjects: 102
Study: 20455609

Group type: EXPERIMENTAL
Intervention: Disruptive confederate child
Number of subjects: 90

Group type: COMPARATOR
Intervention: Typical confederate child
Number of subjects: 90
Study: 18833865

Group type: EXPERIMENTAL
Intervention: Opalescence Xtra Boost (38% HP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Easywhite Ready (30% HP) with plasma unit
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zoom2 system (25% HP with the Zoom2 unit)
Number of subjects: 36

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 36
Study: 16094267

Group type: EXPERIMENTAL
Intervention: Dilute betadine solution irrigation (3.5% betadine) before wound closure
Number of subjects: 414

Group type: COMPARATOR
Intervention: No betadine irrigation (control group)
Number of subjects: 414
Study: 12577416

Group type: EXPERIMENTAL
Intervention: Langchuangding (LCD) plus glucocorticoid (GCC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Glucocorticoid (GCC) alone
Number of subjects: 45
Study: 9647028

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (13-15 mg/kg/day)
Number of subjects: 180
Study: 7518815

Group type: EXPERIMENTAL
Intervention: Combined external irradiation and chemotherapy (bleomycin or peplomycin)
Number of subjects: 162
Study: 2923425

Group type: EXPERIMENTAL
Intervention: Regulated group (n = 41) received hourly aliquots of oral fluid as determined by twice daily ward rounds.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unregulated group (n = 49) were given a jug of water and instructed to drink as desired.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (regulated and unregulated)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients who underwent gastric or duodenal procedures (n = 14)
Number of subjects: 90
Study: 29698720

Group type: EXPERIMENTAL
Intervention: Lidocaine dripped onto the skin prior to injection (1-2 ml)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control group (1% subcutaneous lidocaine injection without prior skin application)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control group for peripherally inserted central catheters (1% subcutaneous lidocaine injection without prior skin application)
Number of subjects: 481
Study: 26812508

Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Dairy consumption (excess vs adequate) among women
Number of subjects: 3076
Study: 25463092

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment for 2 months
Number of subjects: 11
Study: 22515587

Group type: EXPERIMENTAL
Intervention: Mesoglow®
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IAL System®
Number of subjects: 40
Study: 20190354

Group type: EXPERIMENTAL
Intervention: Ecklonia cava polyphenol (ECP) supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18614926

Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Highly Active Antiretroviral Therapy (HAART)
Number of subjects: 37
Study: 16078326

Group type: EXPERIMENTAL
Intervention: Personal interview
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Mailed questionnaire
Number of subjects: 119
Study: 11980742

Group type: EXPERIMENTAL
Intervention: Conscious sedation (2 mg midazolam and 25 microg fentanyl) i.v. 5 min before cervical dilatation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 10895158

Group type: EXPERIMENTAL
Intervention: Docetaxel (single-agent) in second-line NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (single-agent) in first-line NSCLC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel (Phase III randomized study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel (Phase III studies)
Number of subjects: 0
Study: 8828420

Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingostomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Laparoscopic local methotrexate injection
Number of subjects: 48
Study: 1592955

Group type: EXPERIMENTAL
Intervention: CMT (Child Management Training)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CMT plus AST (Adjunctive Ally Support Training)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CMT or CMT plus AST
Number of subjects: 22
Study: 6706437

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 16
Study: 30678333

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg·kg−1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 24
Study: 30126153

Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin) 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin) 600 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard bovine lactoferrin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 12
Study: 26787572

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25424810

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rMenB with reduced OMV doses (0, ¼ or ½ the OMV dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-dose of 4CMenB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prelicensure formulation of 4CMenB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4CMenB (4-dose primary/booster series)
Number of subjects: 0
Study: 22637202

Group type: EXPERIMENTAL
Intervention: Ankle distraction permitting joint motion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fixed ankle distraction
Number of subjects: 36
Study: 20214820

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms measured by the Spielberger State Trait Anxiety Inventory (STAI)
Number of subjects: 1828
Study: 17050578

Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops, twice-daily for 3 days
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Tobramycin 0.3%, 1 drop every two hours for 2 days, then four times daily for 5 days
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops
Number of subjects: 1043
Study: 15960286

Group type: EXPERIMENTAL
Intervention: Eperisone (n=13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Physiotherapy (n=13)
Number of subjects: 26
Study: 11382537

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) consisting of 30 trains of 2‐s duration stimuli (20 Hz, 90% of motor threshold), after 10 daily sessions.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo conditions (sham-rTMS) with identical design but addressing coil discharges to the air.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 7
Study: 9264868

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol (50 micrograms transdermally or 2 mg orally)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcitonin (200 IU every other day)
Number of subjects: 72
Study: 8353409

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 40 micrograms twice daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ethinylestradiol 20 micrograms four times daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with at least 3 adverse reactions
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with one or two adverse reactions
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with nausea and vomiting
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients without nausea and vomiting
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with moderate or severe side effects
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with mild side effects
Number of subjects: 61
Study: 2892452

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2676348

Group type: EXPERIMENTAL
Intervention: Combined high-frequency ventilation (CHFV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Controlled mechanical ventilation (CMV)
Number of subjects: 35
Study: 31463686

Group type: EXPERIMENTAL
Intervention: N-of-1 trial facilitated by a mobile health app
Number of subjects: 215
Study: 31238121

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 780

Group type: COMPARATOR
Intervention: Iodine-alcohol
Number of subjects: 780
Study: 28283779

Group type: EXPERIMENTAL
Intervention: ME-344 10 mg/kg intravenously weekly plus topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day cycle
Number of subjects: 46
Study: 26003334

Group type: EXPERIMENTAL
Intervention: Paleolithic diet for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional heart-healthy diet for 4 months
Number of subjects: 20
Study: 23001292

Group type: EXPERIMENTAL
Intervention: alfentanil 20 μg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ketamine 0.5 mg/kg
Number of subjects: 54
Study: 22073899

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral modifications
Number of subjects: 0
Study: 19893466

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite with the adjunct of a proteolytic enzyme
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard sodium hypochlorite
Number of subjects: 200
Study: 16402229

Group type: EXPERIMENTAL
Intervention: Oily calcium hydroxide suspension (Osteoinductal) applied subgingivally after nonsurgical periodontal therapy
Number of subjects: 19
Study: 14766981

Group type: EXPERIMENTAL
Intervention: Posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 11378598

Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT)
Number of subjects: 80
Study: 9234039

Group type: EXPERIMENTAL
Intervention: Cocaine (25 mg i.v.) administered on 2 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (1 ml i.v.) administered on 1 day
Number of subjects: 8
Study: 8122716

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, 1 percent
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, 1.9 percent
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no hyaluronic acid)
Number of subjects: 117
Study: 2441374

Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing (60/125-150 bpm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fixed rate ventricular pacing (70 bpm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing
Number of subjects: 15
Study: 28990126

Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 114

Group type: COMPARATOR
Intervention: CTG
Number of subjects: 114